A Phase 2 interventional study of BI 764198 and Placebo in Kidney Disease, Chronic, sponsored by Boehringer Ingelheim. Completed at 54 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-12.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Renal Insufficiency, Chronic by Boehringer Ingelheim — none open to participants now, 4 under way, 2 of them phase 3. Renal Insufficiency, Chronic · Boehringer Ingelheim.
Among the 13 studies in Renal Insufficiency, Chronic by Boehringer Ingelheim, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2022, is one of 5 in phase 2, and was the 7th registered.
3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.
Browse Renal Insufficiency, Chronic studies →None of the 13 studies in Renal Insufficiency, Chronic by Boehringer Ingelheim is open now. The open studies under Renal Insufficiency, Chronic, anywhere →
Of the 435 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 111 (26%) stop at 75 or younger; 45 take children under 18; 80 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 67 is close to the median of 73 across 2,162 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 242 across the 10 interventional studies, 1,024 across the 3 observational. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
4 of the studies in Renal Insufficiency, Chronic by Boehringer Ingelheim that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06531824Phase 3Boehringer IngelheimEASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | 2026-12-31 |
| NCT07107945Phase 3Boehringer IngelheimA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | 2027-04-16 |
| NCT07063316Boehringer IngelheimSGLT2 Inhibitors and Renal Anemia in Japan: RWD | 2026-12-25 |
| NCT06527846Boehringer IngelheimPost Marketing Surveillance of JARDIANCE in Chronic Kidney Disease | 2027-03-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 13 studies in Renal Insufficiency, Chronic by Boehringer Ingelheim, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is open to adults with a type of kidney disease called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 improves the health of the kidneys in people with FSGS. Three different doses of BI 764198 are tested in this study.
Participants are put into 4 groups randomly, which means by chance. Three of the groups receive different doses of BI 764198 and one group receives placebo. Participants are in the study for about 4 months. For about 3 months, they take BI 764198 or placebo as capsules once a day.
Placebo capsules look like BI 764198 capsules but do not contain any medicine. Participants visit the study site about 10 times. You can participate in this study from your home. In this case a research nurse will visit you for the study visits.
Kidney health is assessed based on the analysis of urine samples, which participants collect at home. At the end of the study, the results are compared between the different groups. During the study, the doctors also regularly check the general health of the participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Further inclusion criteria apply.
Exclusion criteria:
Further exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with primary focal segmental glomerulosclerosis (FSGS) or patients with monogenic FSGS as a result of TRPC6 mutations took daily one single capsule of 20 milligrams (mg) of BI 764198 orally for 12 weeks.
Drug: BI 764198
Patients with primary focal segmental glomerulosclerosis (FSGS) or patients with monogenic FSGS as a result of TRPC6 mutations took daily one single capsule of 40 milligrams (mg) of BI 764198 orally for 12 weeks.
Drug: BI 764198
Patients with primary focal segmental glomerulosclerosis (FSGS) or patients with monogenic FSGS as a result of TRPC6 mutations took daily one single capsule of 80 milligrams (mg) of BI 764198 orally for 12 weeks.
Drug: BI 764198
Patients with primary focal segmental glomerulosclerosis (FSGS) or patients with monogenic FSGS as a result of TRPC6 mutations took daily one single capsule of placebo-matching BI 764198 orally for 12 weeks.
Drug: Placebo
One single capsule of 20 milligrams (mg), 40 mg, or 80 mg of BI 764198 orally, once a day.
One single capsule of placebo matching BI 764198 orally, once a day.
Achievement of at Least 25% Reduction in 24-hour Urine Protein Creatinine Ratio (UPCR) Relative to Baseline at Week 12
Predicted probability of patients as a percentage - predicted percentage of patients - achieving at least 25% reduction in 24-hour urine protein creatinine ratio (UPCR) relative to baseline at Week 12 (responders) is reported. Baseline was the average of two 24-hour urine samples collected before Visit 2 (Week 0). Patients who either missed their Week 12, 24-hour UPCR assessment or their Week 12, 24-hour UPCR assessment, occurred later than 5 days after the last dose (Residual Effect Period), were considered as non-responders. The predicted probability of response was calculated using a logistic regression utilizing corticosteroid use at randomization and baseline 24-hr UPCR as covariates and is presented as a percentage.
Time frame: At baseline and Week 12.
Relative Change From Baseline at Week 12 of 24-hour Urine Protein Creatinine Ratio (UPCR)
Relative change from baseline at Week 12 in 24-hour urine protein creatinine ratio (UPCR), is reported. Baseline was the average of two 24-hour urine samples collected before Visit 2 (Week 0). An analysis of covariance (ANCOVA) model was used to estimate the relative change in UPCR from baseline to Week 12 with corticosteroid use at randomization and baseline 24-hr UPCR as covariates.
Time frame: At baseline and at Week 12.
Change in 24-hour Urine Protein Creatinine Ratio (UPCR) Relative to Visit 3 at Week 12
Median change in 24-hour urine protein creatinine ratio (UPCR) relative to Visit 3 (Week 1) at Week 12, is calculated by subtracting the 24-hour UPCR, \[Week 12\] - \[Week 1\] values per patient, then by calculating the median of these changes, per treatment group.
Time frame: At Week 1 and Week 12.
Change in 24-hour Urine Protein Creatinine Ratio (UPCR) Relative to Baseline at Week 13
Median change in 24-hour urine protein creatinine ratio (UPCR) relative to baseline at Week 13, is calculated by subtracting the 24-hour UPCR, \[Week 13\] - \[baseline\] values per patient,then by calculating the median of these changes, per treatment group. Baseline was the average of two, 24-hour urine samples collected before Visit 2 (Week 0).
Time frame: At baseline and at Week 13.
Change in 24-hour Urinary Protein Excretion Relative to Baseline at Week 12
Median change in 24-hour urinary excretion rate relative to baseline at Week 12, is calculated by subtracting the urinary excretion rate, \[Week 12\] - \[baseline\], values per patient, then by calculating the median of these changes, per treatment group. Baseline was the average of two, 24-hour urine samples collected before Visit 2 (Week 0).
Time frame: At baseline and at Week 12.
Pre-dose Plasma Concentration of BI 764198 at Steady-state (Cpre,ss ) at Week 4 and Week 12
Pre-dose Plasma Concentration of BI 764198 at steady-state (Cpre,ss ) at Week 4 and Week 12 is reported.
Time frame: At 671.917 hours and at 2015.917 hours after first drug administration.
Randomized, double-blind, parallel group trial to assess the efficacy of 3 doses of BI 764198 (20 mg, 40 mg, and 80 mg) compared to placebo in patients with primary focal segmental glomerulosclerosis (FSGS), or patients with monogenic FSGS as a result of TRPC6 mutations.
| Milestone | BI 764198 20 mg | BI 764198 40 mg | BI 764198 80 mg | Placebo |
|---|---|---|---|---|
| Started | 18 | 16 | 17 | 16 |
| Treated | 18 | 15 | 15 | 14 |
| Completed | 18 | 10 | 15 | 13 |
| Not completed | 0 | 6 | 2 | 3 |
| Withdrew: Adverse event | 0 | 3 | 0 | 0 |
| Withdrew: Protocol deviation | 0 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
| Withdrew: Not treated | 0 | 1 | 2 | 2 |
Predicted probability of patients as a percentage - predicted percentage of patients - achieving at least 25% reduction in 24-hour urine protein creatinine ratio (UPCR) relative to baseline at Week 12 (responders) is reported. Baseline was the average of two 24-hour urine samples collected before Visit 2 (Week 0). Patients who either missed their Week 12, 24-hour UPCR assessment or their Week 12, 24-hour UPCR assessment, occurred later than 5 days after the last dose (Residual Effect Period), were considered as non-responders. The predicted probability of response was calculated using a logistic regression utilizing corticosteroid use at randomization and baseline 24-hr UPCR as covariates and is presented as a percentage.
| Predicted percentage of patients | BI 764198 20 mg | BI 764198 40 mg | BI 764198 80 mg | Placebo |
|---|---|---|---|---|
| Achievement of at Least 25% Reduction in 24-hour Urine Protein Creatinine Ratio (UPCR) Relative to Baseline at Week 12 | 48.9 (29.2 to 68.6) | 16.0 (-1.5 to 33.5) | 38.5 (12.2 to 64.8) | 11.4 (-2.3 to 25.2) |
Relative change from baseline at Week 12 in 24-hour urine protein creatinine ratio (UPCR), is reported. Baseline was the average of two 24-hour urine samples collected before Visit 2 (Week 0). An analysis of covariance (ANCOVA) model was used to estimate the relative change in UPCR from baseline to Week 12 with corticosteroid use at randomization and baseline 24-hr UPCR as covariates.
| Percentage of change in 24-hour UPCR | BI 764198 20 mg | BI 764198 40 mg | BI 764198 80 mg | Placebo |
|---|---|---|---|---|
| Relative Change From Baseline at Week 12 of 24-hour Urine Protein Creatinine Ratio (UPCR) | -38.44 (-50.41 to -23.60) | -2.39 (-24.50 to 26.19) | -21.52 (-39.18 to 1.27) | 2.28 (-20.20 to 31.09) |
Median change in 24-hour urine protein creatinine ratio (UPCR) relative to Visit 3 (Week 1) at Week 12, is calculated by subtracting the 24-hour UPCR, \[Week 12\] - \[Week 1\] values per patient, then by calculating the median of these changes, per treatment group.
| grams/grams | BI 764198 20 mg | BI 764198 40 mg | BI 764198 80 mg | Placebo |
|---|---|---|---|---|
| Change in 24-hour Urine Protein Creatinine Ratio (UPCR) Relative to Visit 3 at Week 12 | -0.035 (-0.812 to 0.669) | 0.712 (-0.169 to 0.926) | -0.4435 (-0.837 to 0.1795) | 0.106 (-0.496 to 0.497) |
Median change in 24-hour urine protein creatinine ratio (UPCR) relative to baseline at Week 13, is calculated by subtracting the 24-hour UPCR, \[Week 13\] - \[baseline\] values per patient,then by calculating the median of these changes, per treatment group. Baseline was the average of two, 24-hour urine samples collected before Visit 2 (Week 0).
| grams/grams | BI 764198 20 mg | BI 764198 40 mg | BI 764198 80 mg | Placebo |
|---|---|---|---|---|
| Change in 24-hour Urine Protein Creatinine Ratio (UPCR) Relative to Baseline at Week 13 | -0.4985 (-0.8080 to 0.5050) | -0.151 (-0.6945 to 0.7650) | -0.3033 (-0.5875 to 0.3830) | 0.0795 (-0.4410 to 1.4615) |
Median change in 24-hour urinary excretion rate relative to baseline at Week 12, is calculated by subtracting the urinary excretion rate, \[Week 12\] - \[baseline\], values per patient, then by calculating the median of these changes, per treatment group. Baseline was the average of two, 24-hour urine samples collected before Visit 2 (Week 0).
| grams/day | BI 764198 20 mg | BI 764198 40 mg | BI 764198 80 mg | Placebo |
|---|---|---|---|---|
| Change in 24-hour Urinary Protein Excretion Relative to Baseline at Week 12 | -0.5036 (-1.6342 to -0.1112) | -0.4056 (-1.0535 to 0.6168) | -0.8967 (-1.0484 to -0.0975) | 0.0809 (-0.8115 to 1.7913) |
Pre-dose Plasma Concentration of BI 764198 at steady-state (Cpre,ss ) at Week 4 and Week 12 is reported.
| nanomole/liter | BI 764198 20 mg | BI 764198 40 mg | BI 764198 80 mg |
|---|---|---|---|
| Week 4 | 119 ± 47.2 | 266 ± 64.7 | 683 ± 66.5 |
| Week 12 | 114 ± 85.9 | 328 ± 64.6 | 509 ± 45.7 |
Collected over All-cause mortality: From first drug-administration until individual end of trial. Up to approximately 16.4 weeks. Adverse event reporting: From first drug administration until stop of treatment + residual effect period (5 days). Up to 14 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BI 764198 20 mg | 0/18 (0%) | 3/18 (16.7%) | 14/18 (77.8%) |
| BI 764198 40 mg | 0/15 (0%) | 0/15 (0%) | 10/15 (66.7%) |
| BI 764198 80 mg | 0/15 (0%) | 1/15 (6.7%) | 10/15 (66.7%) |
| Placebo | 0/14 (0%) | 1/14 (7.1%) | 10/14 (71.4%) |
| Event | BI 764198 20 mg | BI 764198 40 mg | BI 764198 80 mg | Placebo |
|---|---|---|---|---|
| HypertensionVascular disorders | 0/18 | 0/15 | 0/15 | 1/14 |
| Blood creatinine increasedInvestigations | 0/18 | 0/15 | 1/15 | 0/14 |
| OedemaGeneral disorders | 1/18 | 0/15 | 0/15 | 0/14 |
| OsteonecrosisMusculoskeletal and connective tissue disorders | 1/18 | 0/15 | 0/15 | 0/14 |
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 1/18 | 0/15 | 0/15 | 0/14 |
| Event | BI 764198 20 mg | BI 764198 40 mg | BI 764198 80 mg | Placebo |
|---|---|---|---|---|
| FatigueGeneral disorders | 0/18 | 3/15 | 0/15 | 1/14 |
| HeadacheNervous system disorders | 3/18 | 2/15 | 1/15 | 2/14 |
| AnaemiaBlood and lymphatic system disorders | 0/18 | 0/15 | 0/15 | 2/14 |
| NauseaGastrointestinal disorders | 2/18 | 0/15 | 0/15 | 2/14 |
| ConjunctivitisInfections and infestations | 0/18 | 0/15 | 0/15 | 2/14 |
| NasopharyngitisInfections and infestations | 1/18 | 0/15 | 0/15 | 2/14 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/18 | 2/15 | 0/15 | 2/14 |
| Oedema peripheralGeneral disorders | 0/18 | 0/15 | 2/15 | 1/14 |
| Back painMusculoskeletal and connective tissue disorders | 0/18 | 2/15 | 0/15 | 0/14 |
| DizzinessNervous system disorders | 1/18 | 0/15 | 2/15 | 0/14 |
Treated set: all patients who received at least one dose of trial medication.
| Age, Continuous(Years) | BI 764198 20 mg | BI 764198 40 mg | BI 764198 80 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 41.2 ± 15.0 | 39.8 ± 13.8 | 39.8 ± 10.5 | 42.2 ± 11.1 | 40.7 ± 12.6 |
| Sex: Female, Male(Participants) | BI 764198 20 mg | BI 764198 40 mg | BI 764198 80 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 9 | 7 | 2 | 7 | 25 |
| Male | 9 | 8 | 13 | 7 | 37 |
| Ethnicity (NIH/OMB)(Participants) | BI 764198 20 mg | BI 764198 40 mg | BI 764198 80 mg | Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 2 | 2 | 0 | 10 |
| Not Hispanic or Latino | 12 | 13 | 13 | 14 | 52 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | BI 764198 20 mg | BI 764198 40 mg | BI 764198 80 mg | Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 1 |
| Asian | 3 | 3 | 2 | 4 | 12 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 | 0 | 2 |
| Black or African American | 2 | 0 | 1 | 1 | 4 |
| White | 11 | 10 | 9 | 9 | 39 |
| More than one race | 1 | 2 | 1 | 0 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Urine Protein-Creatinine Ratio (UPCR) from 24-hour Urine(Ratio) | BI 764198 20 mg | BI 764198 40 mg | BI 764198 80 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 4.4865 ± 3.0188 | 4.0508 ± 3.0012 | 2.6767 ± 2.2209 | 4.5166 ± 2.9342 | 3.9709 ± 2.8565 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: After structured results have been posted, all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
Data sharing details ↗ · www.mystudywindow.com
Ran from May 2022 to primary completion in Jan 2025, 32 months.
Results were first posted in Jan 2026, 1 year after primary completion.
Of 80 industry-sponsored phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 32 months is above that.
Counting every sponsor, half of 139 studies reached it within 25 months; a quarter within 15 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BI-764198
Renal Insufficiency, Chronic →